Abstract
Sulfonylureas are used to treat patients with type 2 diabetes mellitus when diet and exercise fail. Glimepiride, a new sulfonylurea, can be administered in one daily dose, thanks to its pharmacokinetic properties. We attempted to establish the optimal time of day for the administration of Glimepiride in a group of patients from the Mediterranean area by clinical trial. No relationship was found between the time of administration and fasting blood glucose values, or HbA1c, or the frequency or severity of hypoglycemic episodes.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Blood Glucose / analysis
-
C-Peptide / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Double-Blind Method
-
Fasting
-
Glycated Hemoglobin / analysis
-
Humans
-
Hypoglycemic Agents / administration & dosage*
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use
-
Insulin / blood
-
Lipids / blood
-
Middle Aged
-
Placebos
-
Prospective Studies
-
Sulfonylurea Compounds / administration & dosage*
-
Sulfonylurea Compounds / adverse effects
-
Sulfonylurea Compounds / therapeutic use
-
Time Factors
Substances
-
Blood Glucose
-
C-Peptide
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Insulin
-
Lipids
-
Placebos
-
Sulfonylurea Compounds
-
glimepiride